ZAMBELLI ALBERTO

Didattica

A.A.: 2020/2021

A.A.: 2019/2020

Pubblicazioni

  • Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M., et al. (2020). Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. BREAST CARE, 15(1), 30-37. Dettaglio
  • Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M., et al. (2018). Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) [Altro]. Dettaglio
  • Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Valerio, M., et al. (2018). Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) [Altro]. Dettaglio